SurModics to Webcast Annual Meeting January 30; Special Guests to Discuss Donaldson Joint Development Project
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 23, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Monday, January 30, at 4:00 p.m. CT.
Bruce Barclay, President and Chief Executive Officer, Phil Ankeny, Chief Financial Officer and Vice President, Business Development, and Dale Olseth, Executive Chairman of the Board, will discuss financial results and achievements for the fiscal year ended September 30, 2005 as well as results from the first quarter of fiscal year 2006, and speak about the company's strategy and forward prospects.
In addition, as special guests, SurModics is pleased to welcome Mr. Jim Giertz, Senior Vice President of the Donaldson Company, and Professor Melvin Schindler, the cell biologist from Michigan State University who helped pioneer the opportunity for Donaldson's nanofiber technology in the cell culture field. Dr. Schindler's interests have focused on the development of novel in vitro technologies to measure cell structure and function under conditions that more accurately reflect in vivo cell interactions and organization.
To access the webcast, go to the investor relations portion of the company's web site, www.surmodics.com, on the day of the Annual Meeting and click on the webcast icon. In addition, the Annual Meeting audio and slide presentation will be archived on the company's web site following the meeting.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent and the use of the CELLabration(TM) encapsulation system as an immunoprotective coating for implantable human islet cells. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
CONTACT: SurModics, Inc.
Phil Ankeny, 952-829-2700
SOURCE: SurModics, Inc.